185 related articles for article (PubMed ID: 35750284)
1. High dose (conditioning) regimens used prior to autologous stem cell transplantation in multiple myeloma.
Ali MO; Al Hadidi S
Transplant Cell Ther; 2022 Sep; 28(9):572-580. PubMed ID: 35750284
[TBL] [Abstract][Full Text] [Related]
2. Busulfan plus melphalan versus high-dose melphalan as a conditioning regimen for autologous stem cell transplantation in multiple myeloma with high-risk features (KMM 2015).
Kim M; Lee JJ; Min CK; Lee JY; Jo JC; Yoon SS; Lim SN; Do YR; Kim K; Lee JH; Yoo KH; Bae SH; Yi JH; Jung J; Eom HS; Jung SH
Ann Hematol; 2023 Aug; 102(8):2233-2240. PubMed ID: 37392367
[TBL] [Abstract][Full Text] [Related]
3. Survival outcomes following autologous stem cell transplant with melphalan 140mg/m
Sharma N; Benson E; Zhao Q; Nunnelee J; Cottini F; Elder P; Rosko A; Bumma N; Khan A; Umyarova E; Devarakonda S; Efebera YA; Benson DM
Leuk Lymphoma; 2023; 64(7):1315-1321. PubMed ID: 37199099
[TBL] [Abstract][Full Text] [Related]
4. Final outcomes of escalated melphalan 280 mg/m
Hari P; Reece DE; Randhawa J; Flomenberg N; Howard DS; Badros AZ; Rapoport AP; Meisenberg BR; Filicko-Ohara J; Phillips GL; Vesole DH
Bone Marrow Transplant; 2019 Feb; 54(2):293-299. PubMed ID: 29907806
[TBL] [Abstract][Full Text] [Related]
5. A Phase IIb, Multicenter, Open-Label, Safety, and Efficacy Study of High-Dose, Propylene Glycol-Free Melphalan Hydrochloride for Injection (EVOMELA) for Myeloablative Conditioning in Multiple Myeloma Patients Undergoing Autologous Transplantation.
Hari P; Aljitawi OS; Arce-Lara C; Nath R; Callander N; Bhat G; Allen LF; Stockerl-Goldstein K
Biol Blood Marrow Transplant; 2015 Dec; 21(12):2100-2105. PubMed ID: 26327631
[TBL] [Abstract][Full Text] [Related]
6. High-Dose Melphalan Plus Thiotepa as Conditioning Regimen before Second Autologous Stem Cell Transplantation for "De Novo" Multiple Myeloma Patients: A Phase II Study.
Musso M; Messina G; Marcacci G; Crescimanno A; Console G; Donnarumma D; Scalone R; Pinto A; Martino M
Biol Blood Marrow Transplant; 2015 Nov; 21(11):1932-8. PubMed ID: 26099830
[TBL] [Abstract][Full Text] [Related]
7. A Phase I Trial of High-Dose Lenalidomide and Melphalan as Conditioning for Autologous Stem Cell Transplantation in Relapsed or Refractory Multiple Myeloma.
Mark TM; Guarneri D; Forsberg P; Rossi A; Pearse R; Perry A; Pekle K; Tegnestam L; Greenberg J; Shore T; Gergis U; Mayer S; Van Besien K; Ely S; Jayabalan D; Sherbenou D; Coleman M; Niesvizky R
Biol Blood Marrow Transplant; 2017 Jun; 23(6):930-937. PubMed ID: 28285081
[TBL] [Abstract][Full Text] [Related]
8. BEAM Conditioning Regimen Has Higher Toxicity Compared With High-Dose Melphalan for Salvage Autologous Hematopoietic Stem Cell Transplantation in Multiple Myeloma.
Veeraputhiran M; Jain T; Deol A; Ayash L; Kim S; Dyson G; Bhutani D; Lum LG; Ratanatharathorn V; Uberti JP; Abidi MH
Clin Lymphoma Myeloma Leuk; 2015 Sep; 15(9):531-5. PubMed ID: 26166312
[TBL] [Abstract][Full Text] [Related]
9. A Phase I/II Study of Escalating Doses of Bortezomib in Conjunction with High-Dose Melphalan as a Conditioning Regimen for Salvage Autologous Peripheral Blood Stem Cell Transplantation in Patients with Multiple Myeloma.
Biran N; Rowley SD; Vesole DH; Zhang S; Donato ML; Richter J; Skarbnik AP; Pecora A; Siegel DS
Biol Blood Marrow Transplant; 2016 Dec; 22(12):2165-2171. PubMed ID: 27590107
[TBL] [Abstract][Full Text] [Related]
10. Comparison of conditioning regimen toxicities among autologous stem cell transplantation eligible multiple myeloma patients: High-dose melphalan versus high-dose melphalan and bortezomib.
Aypar E; İzzettin FV; Akı ŞZ; Sancar M; Yeğin ZA; Türköz-Sucak G
J Oncol Pharm Pract; 2018 Jun; 24(4):281-289. PubMed ID: 29284356
[TBL] [Abstract][Full Text] [Related]
11. Intravenous busulfan and melphalan versus high-dose melphalan as a conditioning regimen for early autologous stem cell transplantation in patients with multiple myeloma: a propensity score-matched analysis.
Song GY; Jung SH; Lee JJ; Kim JS; Min CK; Kim K; Choi Y; Eom HS; Joo YD; Kim SH; Kwak JY; Kang HJ; Lee JH; Lee HS; Mun YC; Moon JH; Sohn SK; Park SK; Park Y; Shin HJ; Yoon SS
Leuk Lymphoma; 2020 Nov; 61(11):2714-2721. PubMed ID: 32580672
[TBL] [Abstract][Full Text] [Related]
12. A phase 1/2 of carfilzomib and melphalan conditioning for autologous stem cell transplantation for multiple myeloma (CARAMEL).
Visram A; Hayman SR; Dispenzieri A; Kapoor P; Lacy MQ; Gertz MA; Buadi FK; Dingli D; Warsame R; Kourelis T; Cook J; Binder M; Gonsalves W; Muchtar E; Leung N; Roy V; Rajkumar SV; Kumar S
Am J Hematol; 2023 Aug; 98(8):1277-1285. PubMed ID: 37334773
[TBL] [Abstract][Full Text] [Related]
13. The role of high-dose melphalan with autologous stem-cell transplant in multiple myeloma: is it time for a paradigm shift?
Kazandjian D; Mo CC; Landgren O; Richardson PG
Br J Haematol; 2020 Dec; 191(5):692-703. PubMed ID: 32501533
[TBL] [Abstract][Full Text] [Related]
14. Conditioning regimens in autologous stem cell transplantation for multiple myeloma: a comparative study of efficacy and toxicity from the Spanish Registry for Transplantation in Multiple Myeloma.
Lahuerta JJ; Martinez-Lopez J; Grande C; Bladé J; de la Serna J; Alegre A; García-Laraña J; Caballero D; Sureda A; de la Rubia J; Alvarez AM; Marín J; Escudero A; Conde E; Perez-Equiza K; García Ruiz JC; Moraleda JM; León A; Bargay J; Cabrera R; Hernandez-García MT; Diaz-Mediavilla J; Miguel JS
Br J Haematol; 2000 Apr; 109(1):138-47. PubMed ID: 10848793
[TBL] [Abstract][Full Text] [Related]
15. High-Dose Bendamustine, Etoposide, Cytarabine, and Melphalan (BeEAM) Conditioning Before Autologous Transplantation for Patients With Multiple Myeloma.
Solomon SR; Brown S; Shegda N; Jackson KC; Zhang X; Bashey A; Holland HK; Morris LE; Solh M
Transplant Cell Ther; 2022 Aug; 28(8):486.e1-486.e7. PubMed ID: 35598842
[TBL] [Abstract][Full Text] [Related]
16. Delaying the use of high-dose melphalan with stem cell rescue in multiple myeloma is ready for prime time.
Kazandjian D; Landgren O
Clin Adv Hematol Oncol; 2019 Oct; 17(10):559-568. PubMed ID: 31730582
[TBL] [Abstract][Full Text] [Related]
17. Dose-intensified bendamustine and melphalan (BenMel) conditioning before second autologous transplantation in myeloma patients.
Farag S; Jeker B; Bacher U; Mansouri Taleghani B; Mueller BU; Novak U; Pabst T
Hematol Oncol; 2018 Oct; 36(4):671-678. PubMed ID: 30110717
[TBL] [Abstract][Full Text] [Related]
18. Y
Voegeli M; Rondeau S; Berardi Vilei S; Lerch E; Wannesson L; Pabst T; Rentschler J; Bargetzi M; Jost L; Ketterer N; Bischof Delaloye A; Ghielmini M
Hematol Oncol; 2017 Dec; 35(4):576-583. PubMed ID: 27677906
[TBL] [Abstract][Full Text] [Related]
19. Addressing the questions of tomorrow: melphalan and new combinations as conditioning regimens before autologous hematopoietic progenitor cell transplantation in multiple myeloma.
Martino M; Olivieri A; Offidani M; Vigna E; Moscato T; Fedele R; Montanari M; Console G; Gentile M; Messina G; Irrera G; Morabito F
Expert Opin Investig Drugs; 2013 May; 22(5):619-34. PubMed ID: 23550793
[TBL] [Abstract][Full Text] [Related]
20. Busulfan, Melphalan, and Bortezomib versus High-Dose Melphalan as a Conditioning Regimen for Autologous Hematopoietic Stem Cell Transplantation in Multiple Myeloma.
Rodriguez TE; Hari P; Stiff PJ; Smith SE; Sterrenberg D; Vesole DH
Biol Blood Marrow Transplant; 2016 Aug; 22(8):1391-1396. PubMed ID: 27164062
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]